<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02691572</url>
  </required_header>
  <id_info>
    <org_study_id>R/16.01.17</org_study_id>
    <nct_id>NCT02691572</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane Block Versus Wound Infiltration for Postcesarean Analgesia</brief_title>
  <official_title>Comparison Between Transversus Abdominis Plane Block and Wound Infiltration for Analgesia After Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the analgesic efficacy of transversus abdominis plane block and wound
      infiltration in parturients undergoing cesarean delivery under spinal anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, controlled, double-blind study will be conducted on ASA physical status II
      parturients with full-term singleton pregnancy undergoing elective cesarean delivery under
      spinal anesthesia. Patients will receive either ultrasound-guided transversus abdominis plane
      block or wound infiltration at the end of surgery. After delivery, all patients will receive
      standard analgesia (intravenous ketorolac and oral paracetamol) and patient-controlled
      analgesia with intravenous fentanyl. Total fentanyl consumption at 24 h, pain scores at 2, 4,
      6, 12, and 24 h, side effects, and patient satisfaction will be compared between the 2
      groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative fentanyl dose</measure>
    <time_frame>24 h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative fentanyl dose</measure>
    <time_frame>2, 4, 6, 12 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the first postoperative fentanyl administration</measure>
    <time_frame>24 h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at rest and movement</measure>
    <time_frame>2, 4, 6, 12, and 24 h</time_frame>
    <description>Assessed using 11-point verbal rating scale (0 = no pain, 10 = the worst possible pain), at rest and movement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with nausea and/or vomiting</measure>
    <time_frame>24 h</time_frame>
    <description>The occurrence of nausea and/or vomiting will be observed and recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of sedation</measure>
    <time_frame>24 h</time_frame>
    <description>Assessed using a 4-point scale (1 = awake and alert, 2 = minimally sedated, responds to speech, 3 = moderately sedated, rousable by tactile stimulation, 4 = deeply sedated, rousable only with painful stimulation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pruritis</measure>
    <time_frame>24 h</time_frame>
    <description>The occurrence of pruritis will be assessed by yes/no question and recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of patient satisfaction</measure>
    <time_frame>24 h</time_frame>
    <description>Assessed at 24 h using a 5-point scale (1 = very unsatisfied, 2 = unsatisfied, 3 = fair, 4 = satisfied, 5 = very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Postcesarean Analgesia</condition>
  <arm_group>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). At the end of surgery, 30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing. Sham procedure will be performed after surgery. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cesarean delivery performed under spinal anesthesia (intrathecal bupivacaine 12.5 mg and intrathecal fentanyl 15 µg). After completion of surgery, bilateral ultrasound-guided TAP block will be performed using 20 mL bupivacaine 0.25% on each side. Standard analgesia (ketorolac and paracetamol) and fentanyl patient-controlled analgesia will be administered postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Spinal anesthesia</intervention_name>
    <description>Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal bupivacaine</intervention_name>
    <description>Bupivacaine 12.5 mg will be administered in the subarachnoid space.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal fentanyl</intervention_name>
    <description>Fentanyl 15 µg will be administered in the subarachnoid space.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cesarean delivery</intervention_name>
    <description>Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Wound infiltration</intervention_name>
    <description>30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham procedure</intervention_name>
    <description>Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients` abdomen.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transversus abdominis plane block</intervention_name>
    <description>Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.</description>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>IV ketorolac 30 mg/8 h starting at the end of surgery.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>Oral paracetamol 1 gm/8 h starting 4 h after surgery.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fentanyl patient-controlled analgesia</intervention_name>
    <description>Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.</description>
    <arm_group_label>Wound Infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. American Society of Anesthesiologists physical status II

          2. Full-term singleton pregnancy

        Exclusion Criteria:

          1. Age &lt;19 or &gt; 40 years

          2. Height &lt;150 cm

          3. Weight &lt;60 kg

          4. Body mass index ≥40 kg/m2

          5. Contraindications to spinal anesthesia (patient refusal, increased intracranial
             tension, coagulopathy, uncorrected hypovolemia)

          6. Hypersensitivity to any of the drugs used in the study

          7. Significant cardiovascular, renal, or hepatic disease

          8. Known fetal abnormalities

          9. Emergency situations
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed M Tawfik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesia, Mansoura University Hospitals</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2016</study_first_submitted>
  <study_first_submitted_qc>February 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2016</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed Mohamed Tawfik</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 30, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

